In ₹ Crore except Per Share Latest Annual	BLUEJET FY25	DIVISLAB FY26	AARTIPHARM FY26	CAPLIPOINT FY26	Peer Average
Valuation — at last close
P/E	—	99.89×	48.14×	◆ 28.17×	58.73×
P/B	—	15.28×	◆ 3.96×	5.04×	8.09×
EV/EBITDA	—	73.43×	24.61×	◆ 22.47×	40.17×
Market Cap	—	₹2.56L Cr	₹8,410 Cr	₹18,058 Cr	₹94,188 Cr
Growth
Revenue CAGR 3Y	—	10.78%	-2.20%	◆ 14.25%	7.61%
Revenue CAGR 5Y	—	8.67%	—	◆ 15.56%	12.12%
Net Income CAGR 3Y	—	12.09%	-3.35%	◆ 19.89%	9.54%
Revenue YoY (latest Q)	—	27.80%	◆ 45.92%	19.63%	31.12%
Net Income YoY (latest Q)	—	65.50%	◆ 155.96%	18.79%	80.08%
Profitability
EBITDA Margin	—	32.59%	20.29%	◆ 34.79%	29.22%
Net Income Margin	—	24.32%	9.60%	◆ 29.71%	21.21%
Return on Common Equity	—	16.19%	8.40%	◆ 19.92%	14.84%
Return on Capital Employed	—	17.80%	11.05%	◆ 20.97%	16.61%
Return on Assets	—	13.89%	5.47%	◆ 17.91%	12.42%
Credit & Quality
Total Debt/Equity	—	◆ 0.00×	0.32×	0.00×	0.11×
Interest Coverage	—	129.48×	5.65×	◆ 790.90×	308.68×
Scale — latest FY
Revenue / Total Income	—	₹10,560 Cr	₹1,819 Cr	₹2,187 Cr	₹4,856 Cr
Net Income	—	₹2,568 Cr	₹175 Cr	₹650 Cr	₹1,131 Cr
Total Assets	₹1,418 Cr	₹20,033 Cr	₹3,482 Cr	₹4,045 Cr	₹9,187 Cr -85%
EPS	—	₹96.75	₹19.27	₹84.36	₹66.79
Book Value per Share	—	₹632.49	₹234.35	₹471.9	₹446.25

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 97%.